Home All News

All News

Internet And Biotech Related News

Revive (RVVTF) Hits a Snag?

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 First our summary."FDA provided communication that...

Revive Therapeutics (RVVTF) Annual Shareholder Meeting.

ANNUAL SHAREHOLDER MEETING https://vimeo.com/752050831

13 Keys to a Successful FDA Advisory Committee Meeting (Regulatory Focus)

RAPS' Latest | 01 August 2019 | By Zachary Brousseau  When the US Food and Drug Administration (FDA) has significant...

DCS (DCSX) Announces Closing of Fully Subscribed USD $1.5 Million Private Placement Financing.

San Diego, California--(Newsfile Corp. - September 9, 2022) - Direct Communication Solutions, Inc. (OTCQX: DCSX) (CSE: DCSI) (FSE: 7QU), a leading provider of...

Adding Progressive Care (RXMD) $0.04 to Watch List.

Adding to Biotech Stock Review 2022 Watch List. Speculative, Yes. But Pay Down of $2 Million Toxic Note and...

CB Scientific, Inc. (CBSC) Announces FDA 510(k) Submission.

CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event Monitor Updated product to include significant...

Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital

Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval....

OnFolio Holdings Inc. (ONFO) Announces Pricing of $13.7 Million Initial Public Offering and Nasdaq...

Nice work by EF Hutton. We like this business model. Similar to old school incubator, but they acquire rather than invest and...
Dr John Fahy UCSF

Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

VERU Inc. (VERU). High Risk, Minimal Reward?

Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders. You Can't Kiss all the...

Latest article

ARK VS. SARK | PAST STANCES

Long Ark Innovation 10/3/2022 | $37.90 #ARK, #ARKK, #SARK

ARK vs. SARK

Ever get really, really bearish and really, really wish you could find a simple way to make money in a bear market?

Adding ‘Internet of Things,’ Direct Communications (DCSX) $1.17 to the Watch List.

Chris Bursey, Member of Verizon's Internet of Things (IOT) Advisory Council, Charges Ahead as CEO of Direct Communication (DCSX).